YU39698A - Hinoksalindioni - Google Patents
HinoksalindioniInfo
- Publication number
- YU39698A YU39698A YU39698A YU39698A YU39698A YU 39698 A YU39698 A YU 39698A YU 39698 A YU39698 A YU 39698A YU 39698 A YU39698 A YU 39698A YU 39698 A YU39698 A YU 39698A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- alkyl
- alkoxy
- aryl
- ring
- halo
- Prior art date
Links
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical class C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Pronalazak daje jedinjenje formule (I) i farmacetuski prihvatljive soli od njega u kome je R jedan petočlani prsten heteroaril grupe koja sadrži 3 ili 4 heteroatoma azota povezana sa prstenom hinokasalindiona jednim prstenom atoma ugljenika ili azota, ili je šestočlani prsten hetroaril grupe koja sadrži 1 do 3 heteroatoma azota povezana sa prstenom hinokasalindiona jednim prstenom atoma ugljenika, ili obe navedene grupe opciono benzo-povezane ili opciono supstituirane, uključujući i u benzo-povezanom delu, sa jednim ili dva supstituenta svaki nezavisno izabran između C1-C4 alkil, C2-C4 alkenil, C3-C7 cikloalkil, halo, hidroksi, C1-C4 alkoksi, C3-C7 cikloalkiloksi, -COOH, C1-C4 alkoksikarbonil, -CONR3R4, -NR3R4, -S(O)p(C1-C4 alkil), -SO2NR3R4, aril, ariloksi, aril(C1-C4)alkoksi i het, navedeni C1-C4 alkil opciono supstituiran sa C3-C7 cikloalkil, halo, hidroksi, C1-C4 alkoksi, halo(C1-C4)alkoksi, C3-C7 cikloalkiloksi, C3-C7 cikloalkil(C1-C4 alkoksi, -COOH, C1-C4 alkoksikarbonil, -CONR3R4, -NR3R4, -S(O)p(C1-C4 alkil), -SO2(aril) SO2NR3R4, morfolino, aril, ariloksi, aril(C1-C4)alkoksi ili het, a navedeni C2-C4 alkenil opciono supstituiran arilom; R1 i R2 su svaki nezavisno izabran izmedju H, fluor, hlor, brom, C1-C4 alkil i halo(C1-C4)alkil; R3 i R4 su bilo svaki nezavisno izabran između H i C1-C4 alkil, ili kada su uzeti zajedno, oni su C5-C7 alkilen; p je 0, 1 ili 2; zajedno sa dobijanjem sastava koji ga sadrže, korišćenja istih i intermedijata korišćenih u sintezi takvih jedinjenja. Jedinjenja su korisna kao antagonisti NMDA receptora u tretmanu akutnih neurodegenerativnih i hroničnih neuroloških poremećaja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU39698A true YU39698A (sh) | 1999-03-04 |
Family
ID=10790134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU39698A YU39698A (sh) | 1996-03-09 | 1997-02-27 | Hinoksalindioni |
| YU41199A YU41199A (sh) | 1996-03-09 | 1998-02-24 | Hinoksalindioni |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU41199A YU41199A (sh) | 1996-03-09 | 1998-02-24 | Hinoksalindioni |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6376490B1 (sh) |
| EP (1) | EP0885212B1 (sh) |
| JP (1) | JP3110467B2 (sh) |
| KR (1) | KR100288099B1 (sh) |
| CN (1) | CN1103770C (sh) |
| AP (1) | AP767A (sh) |
| AR (1) | AR006119A1 (sh) |
| AT (1) | ATE208773T1 (sh) |
| AU (1) | AU717972B2 (sh) |
| BG (1) | BG63340B1 (sh) |
| BR (1) | BR9707851A (sh) |
| CA (1) | CA2248366C (sh) |
| CO (1) | CO4770976A1 (sh) |
| CZ (1) | CZ292792B6 (sh) |
| DE (1) | DE69708269T2 (sh) |
| DK (1) | DK0885212T3 (sh) |
| DZ (1) | DZ2188A1 (sh) |
| EA (1) | EA001730B1 (sh) |
| ES (1) | ES2163742T3 (sh) |
| GB (1) | GB9605027D0 (sh) |
| HN (1) | HN1998000034A (sh) |
| HR (1) | HRP970132A2 (sh) |
| HU (1) | HUP9900975A3 (sh) |
| ID (1) | ID18112A (sh) |
| IL (1) | IL125491A (sh) |
| IS (1) | IS4811A (sh) |
| MA (1) | MA26422A1 (sh) |
| NO (1) | NO984058L (sh) |
| NZ (1) | NZ331060A (sh) |
| OA (1) | OA10850A (sh) |
| PE (2) | PE43398A1 (sh) |
| PL (1) | PL329032A1 (sh) |
| PT (1) | PT885212E (sh) |
| SI (1) | SI0885212T1 (sh) |
| SK (1) | SK283467B6 (sh) |
| TN (1) | TNSN97044A1 (sh) |
| TR (1) | TR199801782T2 (sh) |
| TW (1) | TW454004B (sh) |
| UY (1) | UY24482A1 (sh) |
| WO (1) | WO1997032873A1 (sh) |
| YU (2) | YU39698A (sh) |
| ZA (1) | ZA971987B (sh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP982A (en) | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
| JP3588363B2 (ja) * | 1997-02-27 | 2004-11-10 | ファイザー・インク | キノキサリンジオン類 |
| US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| DE10005150A1 (de) | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| WO2001087855A1 (fr) * | 2000-05-19 | 2001-11-22 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| MY145368A (en) * | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
| EP1713101B1 (en) | 2004-02-06 | 2012-10-31 | Yamaguchi University | Electrode for energy storage device and process for producing the same |
| JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CA2686816A1 (en) | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
| WO2008143019A1 (en) | 2007-05-17 | 2008-11-27 | Semiconductor Energy Laboratory Co., Ltd. | Triazole derivative, and light-emitting element, light-emitting device, and electronic device with the use of triazole derivative |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| CN104955809B (zh) * | 2013-02-07 | 2018-12-11 | 普雷斯特威克化学公司 | 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途 |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1，3，4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2550456B2 (ja) * | 1990-11-06 | 1996-11-06 | 山之内製薬株式会社 | 縮合ピラジン誘導体 |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| JP3588363B2 (ja) * | 1997-02-27 | 2004-11-10 | ファイザー・インク | キノキサリンジオン類 |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU39698A (sh) | Hinoksalindioni | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| GB9101660D0 (en) | New compositions of matter | |
| RS50853B (sr) | Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji | |
| PE34996A1 (es) | Nuevo derivado de pirrocarbazol | |
| DE69839753D1 (de) | 2-(Arylphenyl)amino-imidazolin-Derivate | |
| NZ221699A (en) | Pyridazinone derivatives; pharmaceutical compositions and intermediates | |
| FI935798A0 (fi) | Alkylsubstituerade heterocykliska foereningar | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
| HRP20000027B1 (en) | Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds | |
| NO173276C (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive 1,4-disubstituerte-piperidinylderivater | |
| ATE168686T1 (de) | N,n'-disubstituierte amidderivate | |
| DE69626624T2 (de) | Medikamente gegen trhombocytopenie | |
| NO955071L (no) | abeo-Ergolin-derivater som 5HT1A-ligander |